.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR09_EmtricitabineTenofovirDisoproxil.EmtricitabineTenofovirDisoproxil .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR09_EmtricitabineTenofovirDisoproxil.EmtricitabineTenofovirDisoproxil| name: | EmtricitabineTenofovirDisoproxilElvitegravirAndCobicistat |
| ATC code: | J05AR09 | route: | oral |
| n-compartments | 1 |
This fixed-dose combination consists of emtricitabine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), elvitegravir (an integrase inhibitor), and cobicistat (a pharmacokinetic enhancer/booster). The combination is used as a complete regimen for the treatment of HIV-1 infection in adults and adolescents. It is widely approved and used as a single-tablet regimen to improve adherence and reduce pill burden in HIV therapy.
Pharmacokinetic parameters have been reported in healthy adult subjects after oral administration of the fixed-dose combination tablet (once daily). PK parameters reflect values at steady-state.
Ogbuagu, O (2016). Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert review of anti-infective therapy 14(12) 1113–1126. DOI:10.1080/14787210.2016.1255551 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27797606
Yamada, H, et al., & Irie, S (2018). Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. Clinical pharmacology in drug development 7(2) 132–142. DOI:10.1002/cpdd.365 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28581645